PER-125-08已完成未知
A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib
GLAXOSMITHKLINE PERU S.A.,0 个研究点目标入组 4 人开始时间: 2008年12月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 80（—）
入选标准
- •Signed informed consent; have the will and be able to complete all the required components of the study.
- •Histologically confirmed gastric adenocarcinoma, adenocarcinoma of the esophagus or gastroesophageal junction. Pathologic confirmation of the area of metastasis should be performed. The practice of primary tumor biopsy is not necessary. Subjects with pathological confirmation of a metastatic area along with clinical / radiological documentation of gastric implication and no evidence of other primary tumors will also be eligible.
- •Locally advanced non-operable gastric cancer (defined as stage IV: T4N1-3 or TanyN3), metastatic (defined as stage IV: TanyNanyMl) or locally recurrent. Esophageal cancer that is locally advanced and non-operable (T3N1 or T4Nany), metastatic (MI) or locally recurrent. {NdeT: Tany = any stage of the Tumor; Nany — any stage of the node).
- •Measurable or non-measurable but radiologically evaluable disease, according to RECIST [Therasse, 2000]. X-rays, imaging studies, or physical exams for both types of illness (measurable or non-measurable) must be completed within 28 days prior to registration.
- •Positive ErbB2 status evaluated by local laboratory (IHC 3+ or FISH positive or CISH positive). ErbB2 status can be assessed from the primary or metastatic tumor. Subjects with unknown ErbB2 status will not be eligible. All subjects should be provided with tumor tissue upon admission to the study and sent to the central laboratory to determine the centralized state of ErbB2.
- •Age greater than or equal to 18 years.
- •General status of ECOG 2
- •Evaluation of appropriate organic functions within 14 days prior to random distribution. Hematological function: RAN L5xl0 / L, Hemoglobin 9g / dL (with support transfusion, if required), Platelets 100 x 10 / L. Liver function: Total bilirubin 1.5 x UNL (or 2.5 x UNL in case of documented Gilberts syndrome), AST / ALT 3 x UNL (or 5 x UNL in case of documented liver metastasis). Renal function: Serum creatinine 2.0 mg / dL and Creatinine Clearance Calculation 50 mL / min (Cockcroft-Gault method)
- •Cardiac ejection fraction within the normal institutional range as determined by echocardiograms. MUGA studies will be accepted if an echocardiogram cannot be performed or is inconclusive.
- •Ability to ingest and retain oral medication, and / or receive enteral medication through a feeding tube (gastrectomy) (Non-NPO subjects will be considered eligible only after analysis of the study´s medical monitor).
- •Potentially fertile male and female subjects should agree to practice birth control methods during the study.
- •Previous / concurrent therapy.
排除标准
- •Pregnant or breastfeeding women at any time during the study.
- •Known history of active CNS disease.
- •Uncontrolled ascites
- •Concurrent cancer therapies (chemotherapy, radiation therapy, in addition to pain relief therapies, immunotherapy, biological, hormonal therapy or surgery) during the treatment under investigation.
- •Gastric carcinoid, epidermoid, sarcomas or squamous cell carcinoma.
- •Previous palliative chemotherapy for the treatment of gastric cancer.
- •Previous treatment with oxaliplatin or CapeOx regimen
- •Malabsorption syndrome or uncontrolled gastrointestinal inflammatory disease (such as Crohn´s disease or ulcerative colitis).
- •Known history of symptomatic or uncontrolled angina, arrhythmias or congestive heart failure.
- •Sensory or motor neuropathy grade 2 pre-existing by CTC v3.0.
- •Uncontrolled infection.
- •Concurrent illness or condition that could make the subject inappropriate to participate in the study, or any serious medical condition that could interfere with the subject´s safety.
- •History of other malignant tumors except for: Subjects who have not been ill for 5 years, Subjects with a history of fully operable nonmelanoma skin cancer, Subjects with successful treatment of carcinoma in situ.
- •Severe unresolved or unstable toxicity from previous administration of other investigational drugs and / or previous cancer treatments.
- •Dementia, state of mental disorder or any psychiatric condition that could prohibit the understanding or granting of informed consent.
- •Known history of DPD deficiencies.
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib, capecitabine, fluorouracil, platinum or their excipients.
- •The use of any investigational medication within 30 days prior to random distribution.
- •The use of prohibited concurrent medications that could interact with the medications under study, including herbal remedies, traditional Chinese medicines for the treatment of cancer and any other medication or drugs detailed in Table 1.
研究者
相似试验
进行中（未招募）
不适用
A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib - N/ASubjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gastro-oesophageal junction adenocarcinoma.MedDRA version: 9.1Level: LLTClassification code 10001150Term: Adenocarcinoma gastricEUCTR2007-005725-29-EEGlaxoSmithKline Research and Development454
进行中（未招募）
不适用
A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib - N/AEUCTR2007-005725-29-NLGlaxoSmithKline Research and Development410
进行中（未招募）
不适用
A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib - N/ASubjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gastro-oesophageal junction adenocarcinoma.MedDRA version: 9.1Level: LLTClassification code 10001150Term: Adenocarcinoma gastricEUCTR2007-005725-29-HUGlaxoSmithKline Research and Development535
进行中（未招募）
不适用
A PHASE III STUDY OF ERBB2 POSITIVE ADVANCED OR METASTATIC GASTRIC OR ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA TREATED WITH CAPECITABINE PLUS OXALIPLATIN WITH OR WITHOUT LAPATINIB - TRIO-CIRG 013Subjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gsatro-oesophageal junction adenocarcinomaMedDRA version: 14.1Level: LLTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 100000004864EUCTR2007-005725-29-ITGlaxoSmithKline Research and Development410
已完成
3 期
EGF110656 : LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibCTRI/2009/091/000498GlaxoSmithKline Pharmaceuticals Ltd410